Status:
WITHDRAWN
Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19
Lead Sponsor:
Sorrento Therapeutics, Inc.
Conditions:
Covid-19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19
Detailed Description
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™), a COVID-19 targeting monoclonal ant...
Eligibility Criteria
Inclusion
- Evidence of moderate COVID-19, diagnosed standard RT-PCR assay or equivalent testing
- Willing and able to comply with study procedures and follow-up visits
- Subject or family member/caregiver must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating in any study related activity. However, if obtaining written informed consent is not possible, other procedures as provided in the March 27th, 2020 FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic, Question 10, may be used.
Exclusion
- Clinical signs indicative of severe COVID-19
- Rapidly progressive COVID-19 which is likely to progress to "severe" within 24 hours
- Documented infection other than COVID-19
- Any medical condition that, in the Investigator's opinion, could adversely impact safety
- Pregnant or lactating women
- Has participated, or is participating, in a clinical research study evaluating COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. Note: Participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. Additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an Emergency Use Authorization) is allowed.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04454398
Start Date
September 1 2020
End Date
January 1 2021
Last Update
January 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.